Grifols | GRFS - Ebit


Grifols reported EUR411.56M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Arca Biopharma USD -25.09M 5.23M Mar/2025
aTyr Pharma USD -226.49K 140.85K Sep/2025
Bio Path USD -3.24M 616K Mar/2025
Brainstorm Cell Therapeutics USD -3.09M 100K Mar/2025
Capricor Therapeutics USD -24.98M 17.28M Mar/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 411.56M 15.51M Sep/2025
Immunic USD -22.81M 756K Jun/2024
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
TherapeuticsMD USD -1.77M 699K Sep/2023